Publication: Ir(III) Compounds Containing a Terdentate Ligand Are Potent Inhibitors of Proliferation and Effective Antimetastatic Agents in Aggressive Triple-Negative Breast Cancer Cells
Authors
Cutillas Aullo, Natalia ; Ruiz López, José ; Novohradsky, Vojtech ; Marco Calero, Alicia ; Markova, Lenka ; Brabec, Viktor
item.page.secondaryauthor
item.page.director
Publisher
American Chemical Society
publication.page.editor
publication.page.department
DOI
https://doi.org/10.1021/acs.jmedchem.3c00586
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Herein, we report a series of new octahedral iridium(III) complexes Ir1–Ir9 of the type [Ir(N^N^N)(C^N)Cl]PF6 (N^N^N = 4′-(p-tolyl)-2,2′:6′,2″-terpyridine; C^N = deprotonated 2-arylbenzimidazole backbone) to introduce new metal-based compounds for effective inhibition of metastatic processes in triple-negative breast cancer (TNBC). The results show that the structural modifications within the C^N scaffold strongly impact the antimetastatic properties of these complexes in TNBC cells. Furthermore, testing the antimetastatic effects of the investigated Ir complexes revealed that the highest antimetastatic activity in TNBC cells is exhibited by complex Ir1. This result was in contrast to the effects of the clinically used drug doxorubicin used in conventional chemotherapy of TNBC, which conversely promoted metastatic properties of TNBC cells. Thus, the latter result suggests that doxorubicin chemotherapy may increase the risk of metastasis of breast cancer cells, so the search for new drugs to treat breast cancer that would show better antitumor effects than doxorubicin is justified.
publication.page.subject
Citation
Journal of Medicinal Chemistry 2023, 66, 9766−9783
item.page.embargo
Collections
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. http://creativecommons.org/licenses/by/4.0/